PPARγ activation in adipocytes is sufficient for systemic insulin sensitization
Shigeki Sugii, Peter Olson, Dorothy D. Sears et al. · Proceedings of the National Academy of Sciences · 2009
Although peroxisome proliferator-activated receptor gamma (PPARgamma) agonists such as thiazolidinediones (TZDs) are widely used to treat type 2 diabetes, how its activation in individual tissues contributes to TZD's therapeutic action remains controversial. As TZDs are known to have receptor-independent effects, we sought to establish gain-of-function animal models to delineate the receptor's insulin-sensitizing actions. Unexpectedly, we find that selective activation of PPARgamma in adipocytes, but not in macrophages, is sufficient for whole-body insulin sensitization equivalent to systemic TZD treatment. In addition to improved adipokine, inflammatory, and lipid profiles, PPARgamma activation in mature adipocytes normalizes serum insulin without increased adipogenesis. Co-culture studies indicated that PPARgamma-activated adipocytes broadly suppress induction of inflammatory cytokines and C-X-C family chemokines in macrophages. Collectively, these data describe an "adipocentric" model in which adipose activation of PPARgamma is sufficient for complete insulin sensitization and suggest a specific application for fat selective PPARgamma modulators in diabetic therapy.
Cited by 254 works. doi:10.1073/pnas.0912487106
Authors
- Shigeki Sugii
- Peter Olson
- Dorothy D. Sears
- Maziyar Saberi
- Annette R. Atkins
- Grant D. Barish
- Suk-Hyun Hong
- Glenda L. Castro
- Yun-Qiang Yin
- Michael C. Nelson
- Gene Hsiao
- David R. Greaves
- Michael Downes
- Ruth T. Yu
- Jerrold M. Olefsky
- Ronald M. Evans
References
- Obesity is associated with macrophage accumulation in adipose tissue
- An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ)
- Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance
- Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
- mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer.
- PPARγ Mediates High-Fat Diet–Induced Adipocyte Hypertrophy and Insulin Resistance
- PPARγ Is Required for Placental, Cardiac, and Adipose Tissue Development
- Differential Significance of Plasma Visfatin Concentrations according to Adiposity in Children and Adolescents
- Thiazolidinediones
- Macrophage-specific PPARγ controls alternative activation and improves insulin resistance